News: Latest News
Code Biotherapeutics Names David Anderson, PhD, as Chief Scientific Officer
- Dr. Anderson joins growing leadership team following successful funding round in early Summer 2022 to continue advancement of 3DNA® Platform
- Brings more than 20 years of scientific expertise in biotechnology and academia from target identification through post IND drug development in gene therapy field
Greater Philadelphia, Pa., September 28, 2022 — Code Biotherapeutics, Inc., (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announces the appointment of David Anderson, PhD, as Chief Scientific Officer.
“I am thrilled to welcome Dave to the team at this exciting stage of the company’s growth” said Brian P. McVeigh, Code Bio Co-Founder, Chairman, and Chief Executive Officer. “Dave’s leadership and his extensive experience of successfully progressing multiple gene therapy programs from discovery through preclinical development will have a significant impact on the advancement of our growing pipeline of potentially transformative genetic medicines. I look forward to partnering with him to deliver on our promise to treat the untreatable and cure the incurable.”
Dr. Anderson will be responsible for guiding the long-term vision for research and discovery and for driving Code Bio’s overall scientific strategy in Duchenne Muscular Dystrophy (DMD), Type 1 Diabetes (T1D), and other serious diseases. He will lead efforts across research, discovery, translational medicine, regulatory strategy, and early development.
Dr. Anderson joins Code Bio from SwanBio Therapeutics where he served as Senior Vice President, Research directing translation of genetic therapies in development for the treatment of rare neurological diseases of the spinal cord. Prior to his role at SwanBio, Dr. Anderson directed all preclinical research for the treatment of neurological diseases at Spark Therapeutics, Inc., where he oversaw development and growth of the central nervous system portfolio and team during his tenure.
"Genetic medicine has transformed the way scientists and drug developers research and discover therapies, offering hope where before there was none,” said David Anderson, PhD. “I am excited to bring my years of experience in research, discovery and development to Code Bio to help advance their platform and pipeline, while contributing to the proven leadership of the team."
Beyond his experience with SwanBio and Spark, Dr. Anderson also co-founded two early-stage biotechnology companies and previously served as faculty at Thomas Jefferson University. His expertise includes all aspects of experimental design and management with significant experience in molecular discovery and translation of basic research into preclinical animal models to support drug development.
Dr. Anderson received a PhD in Molecular and Cell Biology from Thomas Jefferson University in 2005 and a B.Sc./Hons in Biomedical Sciences from Sheffield Hallam University in 1996.
About Code Bio therapeutics, Inc.
Headquartered in Greater Philadelphia, Code Bio is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The Company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases. For more information, visit www.codebiotx.com.
About Northpond Ventures
Northpond Ventures is a multi-billion-dollar science-driven venture capital firm based in Cambridge, MA; San Francisco, CA; and Bethesda, MD. Northpond has been named one of the three most active lead biotech investors in 2021 by Crunchbase, and the most active lead investor in life science solutions and molecular diagnostics by Silicon Valley Bank. It is particularly engaged in the research ecosystem, having led over 50 financings over the past several years, a high percentage of which have an academic origin. Learn more at npv.vc.
Media Contact:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312-961-2502
mikebeyer@sambrown.com